 |
| apple watch 9 |
The Biden administration upheld the U.S. International Trade Commission's ban on Apple Watch imports related to a patent dispute over the blood oxygen monitor. Effective immediately, the decision impacts Apple Watch Series 9 and Apple Watch Ultra 2, prompting Apple to halt their sales in compliance with the ruling.
At the heart of the legal conflict is the blood oxygen feature, allowing users to monitor oxygen levels in their blood. The ITC found Apple in violation, accusing the tech giant of improperly utilizing blood oxygen technology from medical tech firm Masimo. The Cleveland Clinic underscores the significance of monitoring blood oxygen, linking low levels to severe health issues.
In response to the ITC's order, Apple expressed strong disagreement, vowing to swiftly return the affected watches to U.S. customers. Despite an appeal by Apple, the ban stands.
Masimo, the medical tech company, has not yet responded to CBS News requests for comment.
During a review by a presidential panel, Apple proactively withdrew the devices, anticipating the panel's affirmation of the ITC's decision. The finalization of the exclusion order on December 26, 2023, was confirmed by the U.S. Trade Representative, Ambassador Katherine Tai, who chose not to reverse the ITC's determination.
Introduced with the Series 6 model in 2020, the pulse oximeter feature, which measures blood oxygen levels, has been a notable addition to Apple's smartwatches. It's important to note that the ban excludes the more affordable Apple Watch SE and previously sold watches.
0 Comments